In late 2019, coronavirus was first detected in Wuhan China, later referred to as COVID-19.The virus has spread rapidly to nearly every country on earth with a mortality rate ranging from 0.1-2% depending upon the affected demographic. Affected people may be sick with the virus for 1 to 14 days before developing symptoms. The most common symptoms of coronavirus disease (COVID-19) are fever, tiredness, and dry cough. Most people (about 80%) recover from the disease without needing special treatment. More rarely, the disease can be serious and even fatal. Older people and people with other medical conditions (such as asthma, diabetes, or heart disease) may be more vulnerable to becoming severely ill. This highly contagious virus has been spreading at a rapid rate, resulting in the inundation of medical intensive care units (ICU) and straining international patient care infrastructure. Considering that long-lasting (20-30 days) infections of the respiratory system are to blame for the high mortality rate and the overwhelmed ICU units, assisting the body to suppress this infection in the respiratory system can dramatically improve recovery time and easing ICU patient queues. There is currently no approved countermeasure or vaccine to control the infections of humans with COVID‑19.
Technology Overview
This innovation takes advantage of ferrite (i.e., iron oxide family) nanoparticles for the generation of precisely localized, magnetically induced heat to a specified area of the lung. These particles can enter the deepest recesses of the lung using aerosol inhalers and nebulizers and can be cleared from the body by natural methods without adverse side effects and clearance rates commensurate with the therapeutic thermal and temporal requirements tailored by nanoparticle coating properties.
- Patient‑safe and non‑invasive thermally induced suppression of the virus replication
- Introduction of conjugated and nonconjugated magnetic nanoparticles by aerosol delivery systems 
- Tailored renal clearance 
- Non‑toxicity
- Treatment of temperature-sensitive viral diseases including COVID strains
- License
- Partnering
- Research collaboration
Patent Information:
For Information, Contact:
Colin Sullivan
Commercialization Consultant
Northeastern University
Parisa Andalib
Vincent Harris
aerosol drug delivery
magnetic hyperthermia
superparamagnetic ferrite nanoparticles
suppression of virus replication